Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Provided By GlobeNewswire
Last update: Oct 31, 2024
Data of Blarcamesine confirm upstream SIGMAR1 activation
Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024
Read more at globenewswire.com
